Company profile: Endomag
1.1 - Company Overview
Company description
- Provider of magnetic sensing technologies for breast cancer care, including the Sentimag surgical guidance system to detect tumors and lymph nodes, Magseed markers for precise tissue and lymph node localization, Magtrace lymphatic tracer for sentinel node biopsy with clear signal and visual guidance, and Magseed Pro self-expanding seed for precise deployment and anchoring.
Products and services
- Sentimag: A magnetic-sensing surgical guidance system used to accurately detect tumors and lymph nodes intraoperatively, enabling precise localization during breast cancer surgery
- Magseed: A small metal seed that marks breast cancer or lymph node locations for precise surgical removal, supporting dependable localization and targeted excision
- Magtrace: A lymphatic tracer for sentinel node biopsy procedures that delivers clear signal and visual guidance, helping surgeons identify and track nodes accurately.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Endomag
FogPharma
HQ: United States
Website
- Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking β-catenin inhibitor (Phase 1/2), β-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FogPharma company profile →
Enara Bio
HQ: United Kingdom
Website
- Description: Provider of cancer immunotherapy solutions targeting the T-cell/cancer cell interface, offering the EDAPT platform to discover cancer-specific Dark Antigens, TCR-directed immunotherapies, and off-the-shelf therapeutic cancer vaccines targeting multiple Dark Antigens for broad patient populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enara Bio company profile →
Cytognos
HQ: Spain
Website
- Description: Provider of flow cytometry solutions for blood cancer diagnosis, minimal residual disease detection, and immune monitoring research. Offers Infinicyt software for multicolor data integration and analysis; EuroFlow 8-color antibody panels; OC515 dye; APC-C750 fluorochrome; and Next Generation Flow immunophenotyping protocols.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytognos company profile →
Amphivena Therapeutics
HQ: United States
Website
- Description: Provider of a platform of dual-function biologics in clinical-stage immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amphivena Therapeutics company profile →
Allos Therapeutics
HQ: United States
Website
- Description: Provider of anti-cancer therapeutics, developing and commercializing treatments including FOLOTYN, a folate analogue metabolic inhibitor that accumulates in cancer cells to cause cell death. Also offers Causal AI to predict effects of clinical interventions for complex generics development, and Licensing & Pipeline co-development and drug licensing to make medications more accessible.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Endomag
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Endomag
2.2 - Growth funds investing in similar companies to Endomag
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Endomag
4.2 - Public trading comparable groups for Endomag
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →